
Revvity Inc (RVTY) Stock Forecast & Price Target
Revvity Inc (RVTY) Analyst Ratings
Bulls say
Revvity is expected to experience solid performance in its Life Sciences reagents and Signal Software businesses, with an annual projected growth of 9-11%. The company is also expected to show Long-term (LT) growth of 6-8%, as it capitalizes on its strong diagnostics portfolio, emerging growth areas in pharmaceutical research and allows for expansion potential in e-commerce. Despite current macro pressures, Revvity anticipates a return to positive growth in both biotechnology and diagnostic market sectors, suggesting a healthy financial outlook.
Bears say
Revvity is facing flat earnings per share (EPS) forecasts and diminished operating margin expectations despite growth in its Diagnostics segment. The company adjusted its revenue guidance downwards, from $2.80B-$2.85B to $2.72B-$2.74B, and decreasing its EPS guidance from $4.70-$4.90 to $4.53-$4.57, largely as a result of diminished demand in the Life Sciences segment, specifically, a weaker demand for reagents in the pharma and biotech markets. Moreover, Revvity's future performance may be hampered further by poor economic conditions, industry funding cuts across multiple geographies, and macroeconomic headwinds that lead to slow customer demand for the company's products and services.
This aggregate rating is based on analysts' research of Revvity Inc and is not a guaranteed prediction by Public.com or investment advice.
Revvity Inc (RVTY) Analyst Forecast & Price Prediction
Start investing in Revvity Inc (RVTY)
Order type
Buy in
Order amount
Est. shares
0 shares